Therefore, blocking IFNγ by CREKA-lipo-anti-IFNγ has the potential to prevent capillary leak syndrome and venous thromboembolism in cancer patients undergoing chemotherapy, which merits further studies. Here, IFNG is linked to venous thromboembolism.